Equity Overview
Price & Market Data
Price: $3.89
Daily Change: -$0.11 / 2.83%
Range: $3.71 - $4.19
Market Cap: $198,302,864
Volume: 13,075
Performance Metrics
1 Week: -2.75%
1 Month: -16.52%
3 Months: -45.67%
6 Months: -57.02%
1 Year: -74.51%
YTD: -41.50%
Company Details
Employees: 57
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.